Download PDF
Am J Perinatol
DOI: 10.1055/a-1990-8311
Original Article

Medical Marijuana Legalization in Oklahoma: Effects on Neonatal Exposure to Opiates

Lise DeShea
1   Department of Pediatrics, Neonatal-Perinatal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
,
Shanna Rolfs
2   University of Oklahoma College of Medicine, Oklahoma City, Oklahoma
,
Mike McCoy
3   OU Health, Comanche County Memorial Hospital, Neonatal Intensive Care Unit, Lawton, Oklahoma
,
William H. Beasley
4   Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
,
Edgardo Szyld
1   Department of Pediatrics, Neonatal-Perinatal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
,
Abhishek Makkar
1   Department of Pediatrics, Neonatal-Perinatal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
› Author Affiliations Funding Results from electronic medical records at the University of Oklahoma Health Sciences Center were accessed via the Clinical Research Data Warehouse, which was funded in part by NIH grant (grant no.: U54GM104938) to the Oklahoma Shared Clinical and Translational Resources (OSCTR).
› Further Information
    Permissions and Reprints

Abstract

Objective The U.S. opioid epidemic has been characterized by increases in opioid misuse, overdose deaths, and neonatal opioid withdrawal syndrome. Research suggests that marijuana legalization has contributed to decreased use of opiates, although many studies had methodological weaknesses and failed to address the pregnant population. Implementation of medical cannabis laws has the potential to reduce maternal opioid use and, therefore, neonatal exposure to the drugs. This study aimed to examine the association between Oklahoma's implementation of state medical marijuana laws and the neonatal exposure to opioids.

Study Design Electronic medical records at two sites (Oklahoma City and Lawton) were searched for results of cord, urine, and meconium screens to detect amphetamines, barbiturates, benzodiazepines, cocaine, ethanol, opiates, phencyclidine, and tetrahydrocannabinol (THC). Two study periods were compared: 19 months before Oklahoma's medical marijuana law took effect and 19 months after legalization began.

Results A total of 16,804 babies were born alive at the two sites during the study period. The rate of positive THC tests per 1,000 liveborn infants significantly increased from 16.2 per 1,000 during the prelaw period to 22.2 per 1,000 during the postlaw period (p = 0.004). Neonatal opioid exposure incidence showed a nonsignificant decrease from 7.6 positive tests per 1,000 liveborn infants to 6.8 per 1,000 from prelaw to postlaw period (p = 0.542). The number of positive tests for THC and concomitant use of opioids doubled from the prelaw period (n = 4) to postlaw (n = 9), but there were too few cases for statistical significance. Infants at the more rural site had significantly higher rates for amphetamines, benzodiazepines, and THC, with a trend toward higher rates for opiates.

Conclusion Marijuana legalization was related to significant increases in positive test rates for THC, but no significant change/association was noted for neonatal exposure to opioids.

Key Points

  • Prior studies have not examined neonatal exposure to opioids following marijuana legalization.

  • Oklahoma's new law led to higher neonatal marijuana exposure.

  • Legalization of medical marijuana did not change Oklahoma's neonatal opioid positivity rate.

Keywords

medical marijuana laws - marijuana legalization - opioids - neonatal opioid withdrawal syndrome - neonatal exposure to opioids

Authors' Contributions

L. D.: first author; conception and design; acquisition and interpretation of data; drafting and revision of the article; final approval.

S. R.: conception and design; revision of the article; and final approval.

M. M.: acquisition of data and final approval.

W. H. B.: acquisition and interpretation of data and final approval.

E. S.: interpretation of data; drafting and revision of the article; and final approval.

A. M.: senior author; conception and design; acquisition and interpretation of data; drafting and revision of the article; and final approval.




Publication History

Received: 02 April 2022

Accepted: 22 November 2022

Accepted Manuscript online:
30 November 2022

Article published online:
16 January 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 NIH. Opioid overdose crisis. 2020 Revised April 2020. Accessed December 20, 2022 at: https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis
    PubMed
  • 2 Centers for Disease Control and Prevention. U.S. state opioid dispensing rates, 2020. September 22, 2021 [cited October 18, 2021]. Accessed December 20, 2022 at: https://www.cdc.gov/drugoverdose/rxrate-maps/state2020.html
    PubMed
  • 3 Centers for Disease Control and Prevention. 2019 drug overdose death rates. March 22, 2021 [cited 2021 October 18, 2021]. Accessed December 20, 2022 at: https://www.cdc.gov/drugoverdose/deaths/2019.html
    PubMed
  • 4 Ko JY, D'Angelo DV, Haight SC. et al. Vital signs: prescription opioid pain reliever use during pregnancy - 34 U.S. jurisdictions, 2019. MMWR Morb Mortal Wkly Rep 2020; 69 (28) 897-903
    CrossrefPubMedGoogle Scholar
  • 5 Chihuri S, Li G. State marijuana laws and opioid overdose mortality. Inj Epidemiol 2019; 6: 38
    CrossrefPubMedGoogle Scholar
  • 6 Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med 2014; 174 (10) 1668-1673
    CrossrefPubMedGoogle Scholar
  • 7 Verilife Blog. United States of weed. Cited October 21, 2021. Accessed December 20, 2022 at: https://www.verilife.com/blog/united-states-weed
    PubMed
  • 8 Centers for Disease Control and Prevention. Opioid use during pregnancy. Available at: https://www.cdc.gov/pregnancy/opioids/basics.html
    PubMed
  • 9 Ernst KD, Makkar A. The opioid-exposed neonate: a review of the Oklahoma experience. J Okla State Med Assoc 2018; 111 (08) 768-774
    PubMedGoogle Scholar
  • 10 NIDA. Opioid summaries by state. Revised April 2020. Accessed December 20, 2022 at: https://www.drugabuse.gov/drugs-abuse/opioids/opioid-summaries-by-state
    PubMed
  • 11 Liang D, Bao Y, Wallace M, Grant I, Shi Y. Medical cannabis legalization and opioid prescriptions: evidence on US Medicaid enrollees during 1993-2014. Addiction 2018; 113 (11) 2060-2070
    CrossrefPubMedGoogle Scholar
  • 12 Hill KP, Saxon AJ. The role of cannabis legalization in the opioid crisis. JAMA Intern Med 2018; 178 (05) 679-680
    CrossrefPubMedGoogle Scholar
  • 13 Shah A, Hayes CJ, Lakkad M, Martin BC. Impact of medical marijuana legalization on opioid use, chronic opioid use, and high-risk opioid use. J Gen Intern Med 2019; 34 (08) 1419-1426
    CrossrefPubMedGoogle Scholar
  • 14 Shi Y, Liang D, Bao Y, An R, Wallace MS, Grant I. Recreational marijuana legalization and prescription opioids received by Medicaid enrollees. Drug Alcohol Depend 2019; 194: 13-19
    CrossrefPubMedGoogle Scholar
  • 15 Vyas MB, LeBaron VT, Gilson AM. The use of cannabis in response to the opioid crisis: a review of the literature. Nurs Outlook 2018; 66 (01) 56-65
    CrossrefPubMedGoogle Scholar
  • 16 Wen H, Hockenberry JM. Association of medical and adult-use marijuana laws with opioid prescribing for Medicaid enrollees. JAMA Intern Med 2018; 178 (05) 673-679
    CrossrefPubMedGoogle Scholar
  • 17 McMichael BJ, Van Horn RL, Viscusi WK. The impact of cannabis access laws on opioid prescribing. J Health Econ 2020; 69: 102273
    CrossrefPubMedGoogle Scholar
  • 18 Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients. Int J Drug Policy 2017; 42: 30-35
    CrossrefPubMedGoogle Scholar
  • 19 Kropp Lopez AK, Nichols SD, Chung DY, Kaufman DE, McCall KL, Piper BJ. Prescription opioid distribution after the legalization of recreational marijuana in Colorado. Int J Environ Res Public Health 2020; 17 (09) 3251
    CrossrefPubMedGoogle Scholar
  • 20 Chan NW, Burkhardt J, Flyr M. The effects of recreational marijuana legalization and dispensing on opioid mortality. Econ Inq 2020; 58 (02) 589-606
    CrossrefPubMedGoogle Scholar
  • 21 Powell D, Pacula RL, Jacobson M. Do medical marijuana laws reduce addictions and deaths related to pain killers?. J Health Econ 2018; 58: 29-42
    CrossrefPubMedGoogle Scholar
  • 22 Livingston MD, Barnett TE, Delcher C, Wagenaar AC. Recreational cannabis legalization and opioid-related deaths in Colorado, 2000–2015. Am J Public Health 2017; 107 (11) 1827-1829
    CrossrefPubMedGoogle Scholar
  • 23 Finn K. Why marijuana will not fix the opioid epidemic. Mo Med 2018; 115 (03) 191-193
    PubMedGoogle Scholar
  • 24 Olfson M, Wall MM, Liu SM, Blanco C. Cannabis use and risk of prescription opioid use disorder in the United States. Am J Psychiatry 2018; 175 (01) 47-53
    CrossrefPubMedGoogle Scholar
  • 25 Li G, Chihuri S. Is marijuana use associated with decreased use of prescription opioids? Toxicological findings from two US national samples of drivers. Subst Abuse Treat Prev Policy 2020; 15 (01) 12
    CrossrefPubMedGoogle Scholar
  • 26 Caputi TL, Humphreys K. Medical marijuana users are more likely to use prescription drugs medically and nonmedically. J Addict Med 2018; 12 (04) 295-299
    CrossrefPubMedGoogle Scholar
  • 27 Lee E, Pluym ID, Wong D, Kwan L, Varma V, Rao R. The impact of state legalization on rates of marijuana use in pregnancy in a universal drug screening population. J Matern Fetal Neonatal Med 2022; 35 (09) 1660-1667
    CrossrefPubMedGoogle Scholar
  • 28 Gnofam M, Allshouse AA, Stickrath EH, Metz TD. Impact of marijuana legalization on prevalence of maternal marijuana use and perinatal outcomes. Am J Perinatol 2020; 37 (01) 59-65
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Shah DS, Turner EL, Chroust AJ, Duvall KL, Wood DL, Bailey BA. Marijuana use in opioid exposed pregnancy increases risk of preterm birth. J Matern Fetal Neonatal Med 2022; 35 (25) 8456-8461
    CrossrefPubMedGoogle Scholar
  • 30 Straub HL, Mou J, Drennan KJ, Pflugeisen BM. Maternal marijuana exposure and birth weight: an observational study surrounding recreational marijuana legalization. Am J Perinatol 2021; 38 (01) 65-75
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Siega-Riz AM, Keim-Malpass J, Lyons GR, Alhusen J. The association between legalization of recreational marijuana use and birth outcomes in Colorado and Washington state. Birth Defects Res 2020; 112 (09) 660-669
    CrossrefPubMedGoogle Scholar
  • 32 Paulozzi LJ, Xi Y. Recent changes in drug poisoning mortality in the United States by urban-rural status and by drug type. Pharmacoepidemiol Drug Saf 2008; 17 (10) 997-1005
    CrossrefPubMedGoogle Scholar
  • 33 USDA Economic Research Service. What is rural? October 23, 2019. Accessed December 20, 2022 at: https://www.ers.usda.gov/topics/rural-economy-population/rural-classifications/what-is-rural.aspx
    PubMed
  • 34 Young NK, Gardner S, Otero C. et al. Substance-Exposed Infants: State Responses to the Problem. Rockville, MD: US Department of Health and Human Services; 2009
    Google Scholar